


CLAIMS

What is claimed is:


1. A compound having the general formula:



, wherein R comprises a linear, saturated alkyl having from 4 to 18 carbons, or a pharmaceutically acceptable salt thereof.


2. The compound of claim 1, wherein R comprises a linear, saturated alkyl having from 11 to 16 carbons.

3. The compound of claim 1, wherein the compound is




, or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1, wherein the compound is



, or a pharmaceutically acceptable salt thereof.


5. The compound of claim 1, wherein the compound is



, or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1, comprising a pharmaceutically acceptable salt, and wherein the salt is one of monohydrate and hyclate.


7. A pharmaceutical composition for preventing metastasis, the composition comprising a compound having the general formula:



, wherein R comprises a linear, saturated alkyl having from 4 to 18 carbons, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.


8. The pharmaceutical composition of claim 7, wherein R comprises a linear, saturated alkyl having from 11 to 16 carbons.

9. The pharmaceutical composition of claim 7, wherein the compound is




pharmaceutically acceptable salt thereof.

10. The pharmaceutical composition of claim 7, wherein the compound is



pharmaceutically acceptable salt thereof.

11. The pharmaceutical composition of claim 7, wherein the compound is



pharmaceutically acceptable salt thereof.

12. The pharmaceutical composition of claim 7, comprising a pharmaceutically acceptable salt, and wherein the salt is one of monohydrate and hyclate.
13. The pharmaceutical composition of claim 7, wherein the pharmaceutically acceptable carrier comprises at least one of a sugar, a starch, cellulose, an excipient, an oil, a glycol, a polyol, an ester, an agar, and a buffering agent.
14. The pharmaceutical composition of any of claims 7-13, for use in one of preventing metastasis, reducing inflammation, reducing fibrosis, and reducing viral replication.
15. A method for preventing metastasis in a patient, the method comprising administering to the patient a pharmaceutically effective amount of a pharmaceutical composition of any of claims 7-13.
16. A method for reducing inflammation in a patient, the method comprising administering to the patient a pharmaceutically effective amount of a pharmaceutical composition of any of claims 7-13.
17. A method for reducing fibrosis in a patient, the method comprising administering to the patient a pharmaceutically effective amount of a pharmaceutical composition of any of claims 7-13.
18. A method for reducing virus replication in a patient, the method comprising administering to the patient a pharmaceutically effective amount of a pharmaceutical composition of any of claims 7-13.